China National Medicines Corporation Ltd.

SHSE:600511 Stok Raporu

Piyasa değeri: CN¥24.0b

China National Medicines Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

China National Medicines has a total shareholder equity of CN¥18.5B and total debt of CN¥284.3M, which brings its debt-to-equity ratio to 1.5%. Its total assets and total liabilities are CN¥34.3B and CN¥15.9B respectively. China National Medicines's EBIT is CN¥2.3B making its interest coverage ratio -4.1. It has cash and short-term investments of CN¥8.3B.

Anahtar bilgiler

1.5%

Borç/özkaynak oranı

CN¥284.32m

Borç

Faiz karşılama oranı-4.1x
NakitCN¥8.30b
EşitlikCN¥18.46b
Toplam yükümlülüklerCN¥15.88b
Toplam varlıklarCN¥34.34b

Son finansal sağlık güncellemeleri

Recent updates

The China National Medicines Corporation Ltd. (SHSE:600511) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

Oct 25
The China National Medicines Corporation Ltd. (SHSE:600511) Third-Quarter Results Are Out And Analysts Have Published New Forecasts

China National Medicines Corporation Ltd.'s (SHSE:600511) Prospects Need A Boost To Lift Shares

Sep 26
China National Medicines Corporation Ltd.'s (SHSE:600511) Prospects Need A Boost To Lift Shares

Calculating The Fair Value Of China National Medicines Corporation Ltd. (SHSE:600511)

Sep 10
Calculating The Fair Value Of China National Medicines Corporation Ltd. (SHSE:600511)

Returns On Capital At China National Medicines (SHSE:600511) Paint A Concerning Picture

Jul 28
Returns On Capital At China National Medicines (SHSE:600511) Paint A Concerning Picture

China National Medicines Corporation Ltd.'s (SHSE:600511) Low P/E No Reason For Excitement

Jun 24
China National Medicines Corporation Ltd.'s (SHSE:600511) Low P/E No Reason For Excitement

China National Medicines (SHSE:600511) Has Announced That It Will Be Increasing Its Dividend To CN¥0.854

Jun 07
China National Medicines (SHSE:600511) Has Announced That It Will Be Increasing Its Dividend To CN¥0.854

Is China National Medicines (SHSE:600511) Using Too Much Debt?

Jun 05
Is China National Medicines (SHSE:600511) Using Too Much Debt?

Calculating The Fair Value Of China National Medicines Corporation Ltd. (SHSE:600511)

May 21
Calculating The Fair Value Of China National Medicines Corporation Ltd. (SHSE:600511)

Capital Allocation Trends At China National Medicines (SHSE:600511) Aren't Ideal

Apr 10
Capital Allocation Trends At China National Medicines (SHSE:600511) Aren't Ideal

China National Medicines (SHSE:600511) Could Easily Take On More Debt

Feb 28
China National Medicines (SHSE:600511) Could Easily Take On More Debt

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 600511's short term assets (CN¥29.8B) exceed its short term liabilities (CN¥14.6B).

Uzun Vadeli Yükümlülükler: 600511's short term assets (CN¥29.8B) exceed its long term liabilities (CN¥1.3B).


Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 600511 has more cash than its total debt.

Borcun Azaltılması: 600511's debt to equity ratio has reduced from 4.2% to 1.5% over the past 5 years.

Borç Kapsamı: 600511's debt is well covered by operating cash flow (593.5%).

Faiz Kapsamı: 600511 earns more interest than it pays, so coverage of interest payments is not a concern.


Bilanço


Sağlıklı şirketleri keşfedin